Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Sulforaphane may protect hair follicles by reducing inflammation and oxidative stress.

Exosomes are tiny vesicles that promote hair regeneration by signaling hair follicle cells.

GT20029's effectiveness compared to finasteride or RU58841 is still unproven.

No PP405 mask exists to test: PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, it is not an anti-DHT ingredient, and it is not on sale. Its registered Phase 2 trial (NCT06393452) measured safety, not regrowth, and a rinse-out mask is in any case the wrong format for reaching the follicle.

TDM-105795 targets thyroid hormone receptors, differing from established treatments like minoxidil and finasteride.

Procapil's supplier describes it as inhibiting 5-alpha reductase at the scalp without changing hormone levels, but the published support is cell and animal work plus one small human study of a caffeine-plus-Procapil formula. It is a cosmetic ingredient, not an approved hair-loss treatment, and no trial has compared it with finasteride or minoxidil.

Procapil is a cosmetic ingredient complex; laboratory studies of its individual ingredients report anti-inflammatory effects, but no published clinical trial has tested it in alopecia areata or any other immune-related hair loss. Spreading bald patches should be assessed by a dermatologist.

HMI-115 is administered as an injection.

No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.

SCUBE3 is not available as a topical or injectable treatment and is not an approved medicine. In the published research it was delivered by microinjecting the recombinant protein into mouse skin and into cultured or grafted human follicles; there are no human clinical trials.

There is no published trial of Baicapil in alopecia areata. The anti-inflammatory and hair-density claims come from the ingredient's manufacturer and from laboratory work on its plant extracts, in people with androgenetic-type hair loss rather than autoimmune patchy hair loss.

Osteopontin aids scalp healing by attracting immune cells and promoting growth factors.

L-cysteine supports hair growth by strengthening keratin, the main protein in hair.

There is no published trial showing that any one group benefits most from HMI-115: the only released human efficacy data is a company press release on a 16-person Phase 1b, and it reported hair-count results for the 12 men only.

Centella asiatica has anti-inflammatory and wound-healing effects in animal and cell studies, but no published research has tested a centella scalp mask on the human scalp, in hormonal contexts or otherwise, and no community reports were found of one being used this way.

Omega-3 can reduce scalp inflammation, potentially preventing sudden hair loss.

SCUBE3 is not currently proven to help with androgenetic alopecia.

There is no completed human trial of GHK-Cu for androgenetic alopecia, so it cannot be compared with minoxidil or finasteride on evidence; clinics and community users treat it as an unproven add-on, not a replacement.

Not yet. GT20029 is an experimental drug: early trials suggest it is well tolerated, but its effectiveness and long-term safety are unproven, especially in women.

Follistatin blocks activin and related growth-inhibiting proteins, which in laboratory and animal work is described as keeping hair follicles in their growth phase; the only verifiable human evidence is a single small 2011 phase 1 injection trial, so follistatin remains experimental and is not an approved hair-loss treatment.

Alopecia areata patches usually still have living follicles. Peptides are being studied as a possible add-on, but the evidence is small and early. See a dermatologist for treatment.

Selenium is essential for hair health due to its antioxidant properties and role in thyroid function.

There is no approved exosome treatment for hair loss and no controlled trial in either mild or advanced cases; the argument that early thinning would respond better is based on follicle biology, not on results.

TDM-105795 may target non-scarring alopecia, particularly androgenetic alopecia.

Thymosin Beta 4 is primarily being explored as a topical treatment for hair loss.

Studies link low serum zinc to diffuse shedding and alopecia areata, and severe deficiency states cause hair loss that reverses when zinc is replaced. The evidence is mostly observational, the one supplementation study was small and uncontrolled, and zinc is not a treatment for pattern hair loss.

Keratin strengthens hair by forming protective structures that prevent breakage and thinning.

TDM-105795 is an experimental drug aimed at treating androgenetic alopecia to promote hair growth.

Capsicum may irritate sensitive scalps and worsen inflammatory hair loss.

KY19382 is an experimental hair growth compound targeting the Wnt/β-catenin pathway, unlike minoxidil and finasteride.